Source: NETAG
Area: Evidence > Drug Specific Reviews
The North East Treatment Advisory Group (NETAG) has produced an updated appraisal of bevacizumab for the management of neovascular age-related macular degeneration and recommended bevacizumab 1.25 …
Author: NeLM - Ophthalmology
NETAG supports use of intravitreal bevacizumab for the management of age-related macular degeneration
Source: NETAG
Area: News
The North East Treatment Advisory Group (NETAG) has produced an updated appraisal of bevacizumab for the management of neovascular age-related macular degeneration and recommended bevacizumab 1.25 mg intravitreal injection as…
SMC does not recommend ranibizumab (Lucentis®) for diabetic macular oedema
Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium (SMC) does not recommend ranibizumab (Lucentis®) for use within NHS Scotland for the treatment of visual impairment due to diabetic m…
DTB: Management of acute infective conjunctivitis
Source: DTB
Area: Evidence > Disease Focused Reviews
This review in the Drug and Therapeutics Bulletin (DTB) examines the evidence on the efficacy of antibacterials in acute infective conjunctivitis and provides practical information and advice for pr…
Two-year data from RISE and RIDE studies of ranibizumab in diabetic macular oedema presented at conference
Source: BioSpace.com
Area: News
BioSpace has reported on the 24-month results from the Phase III RIDE and RISE studies, which evaluated the efficacy and safety of ranibizumab (Lucentis) in the treatment of diabetic macular oedema (DMO). These fi…
Study finds latanoprost non-inferior to timolol for paediatric glaucoma
Source: Ophthalmology
Area: News
According to the results of this head-to-head study published early online in Ophthalmology, latanoprost was non-inferior to timolol for the treatment of glaucoma in children.
The authors note that there ha…
CHMP does not recommend approval of voclosporin (Luveniq®) for chronic non-infectious uveitis
Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recommending that a marketing authorisation should not be granted for the orphan medicine voclosporin (Luveniq®), …
A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications
Source: Eye
Area: Evidence > Medicines Management > References
Purpose: To learn from patient safety incidents (PSIs) following recent introduction of vascular endothelial growth factor inhibitor medications (anti-VEGF) in ophthalmic care, as reported…
Eyecare commissioning guidance launched
Source: NHS Networks
Area: News
New eye care commissioning guidance has been launched which is aimed at helping clinical commissioning groups to provide quality, cost-effective eye care services for their patients. Produced in collaboration with leadi…
Horizon scanning: FDA Advisory Committee recommends approval of aflibercept ophthalmic solution (Eylea®) for wet AMD
Source: PharmaLive
Area: News
According to PharmaLive, the Dermatologic and Ophthalmic Drugs Advisory Committee of the US FDA has voted unanimously to recommend the approval of aflibercept ophthalmic solution (Eylea®; also known as VEGF Trap-Eye) for…
Novel drug delivery systems for glaucoma
Source: Eye
Area: Evidence > Medicines Management > References
Reduction of intraocular pressure (IOP) by pharmaceutical or surgical means has long been the standard treatment for glaucoma. A number of excellent drugs are available that are effe…
Bayer Healthcare applies for EU marketing authorisation of aflibercept for treatment of wet age-related macular degeneration
Source: BioSpace.com
Area: News
According to a report by BioSpace, Bayer HealthCare has submitted an application for marketing authorisation to the EMA for VEGF Trap-Eye (aflibercept) for the treatment of the neovascular form of age-related macular de…
Ranibizumab (Lucentis®) approved in the EU for the treatment of vision loss due to macular oedema secondary to retinal vein occlusion
Source: PharmaLive
Area: News
According to a report by PharmaLive, the European Commission has approved a new indication for ranibizumab (Lucentis®) – to treat patients with visual impairment due to macular oedema secondary to retinal vein occlusion …